Peptide-MHC Target Nanobody Discovery

TCR-Mimic Nanobody Discovery for Peptide-MHC Targeting

Because peptide-MHC complexes often differ by only a few amino acids, TCRm discovery requires exceptional specificity and precise discrimination between closely related epitopes. Off-target recognition remains one of the primary challenges in TCRm development.

To support high-specificity pMHC targeting, our discovery workflows integrate specialized antigen presentation strategies, high-stringency screening approaches, and quantitative display technologies to enable efficient identification of TCR-mimic nanobody candidates.

Why Nanobodies for TCR-Mimic Discovery?

TCR-mimic discovery requires binders capable of recognizing highly specific peptide-MHC conformations while minimizing cross-reactivity. Nanobodies are particularly suitable for this application due to several unique properties.

Recognition of Conformational Epitopes

The compact VHH structure enables access to structurally restricted peptide-MHC surfaces.

High Specificity Potential

Nanobody-based screening strategies can support stringent selection against closely related pMHC complexes.

Excellent Engineering Flexibility

Suitable for TCRm-CAR, bispecific molecules, and targeted delivery applications.

Key Challenges in TCR-Mimic Discovery

TCRm discovery presents unique technical challenges compared with conventional antibody discovery.

High pMHC Similarity

Closely related peptide-MHC complexes require extremely selective binders.

Limited Epitope Accessibility

Peptide epitopes are partially buried within MHC grooves.

Off-Target Binding Risk

Cross-reactivity with unrelated peptide-MHC complexes must be minimized.

Functional Specificity Requirement

Binders must recognize physiologically relevant pMHC conformations on cell surfaces.

Advantages Our TCR-Mimic Discovery Strategy

High-Stringency Yeast Display Screening:

Positive selection against target pMHC complexes

Negative screening against related pMHC complexes

Real-time affinity-based sorting

Enrichment of highly specific clones

These approaches help enrich highly selective TCRm nanobody candidates while minimizing off-target recognition.

Screening Workflow for TCR-Mimic Nanobody Discovery

TCR-Mimic Nanobody Discovery for Peptide-MHC Targeting

Deliverables

Clients will receive:

TCR-mimic nanobody sequences

Specificity validation data

Expression-ready constructs (optional)

Comprehensive project report

Optional downstream services

Affinity maturation

Nanobody humanization

Typical Project Timeline

Stage	Deliverables	Timeline
Immunization	Serum titer report	8 weeks
Library construction	Immune phage or yeast display library	3–4 weeks
Library screening	TCR-mimic nanobody candidates	4-6 weeks
Optional candidate production	Purified VHH and expression-ready constructs	2–3 weeks
Optional validation	Specificity and cell-binding assays	2–4 weeks

Advantages of Our Peptide-MHC Target Nanobody Discovery Platform

Peptide-MHC target nanobody discovery requires more than conventional antigen-binding screening. A successful TCR-mimic binder must recognize a specific peptide presented by its corresponding MHC molecule while discriminating against unrelated peptide-MHC complexes. NBbiolab integrates specialized pMHC antigen presentation, high-stringency yeast display screening, and specificity-oriented candidate evaluation to support the discovery of TCR-mimic nanobodies for targeted therapeutic research.

pMHC-Focused Antigen Presentation

Peptide-MHC complexes contain two recognition components: the presented peptide and the MHC molecule. Their combined molecular surface forms the target epitope recognized by TCR-mimic binders. Proper peptide loading, HLA allele selection, and antigen quality are therefore essential for establishing a suitable screening system.

Project-specific pMHC antigen formats can be evaluated according to peptide sequence, HLA restriction, complex stability, and downstream screening requirements.

High-Specificity Yeast Display Screening

Yeast surface display provides a platform for selecting VHH candidates against target pMHC complexes. Positive selection enriches binders recognizing the desired peptide-HLA complex, while negative selection against unrelated or closely related pMHC complexes helps reduce non-specific recognition.

Fluorescence-activated cell sorting (FACS) supports quantitative enrichment and comparison of candidate populations under defined screening conditions.

Peptide-Dependent Recognition Assessment

A key objective in TCR-mimic discovery is to identify candidates that recognize the target peptide in the context of the correct MHC molecule, rather than binding only to the shared MHC framework. Comparing target and control pMHC complexes helps evaluate whether candidate binding depends on the intended peptide-HLA combination.

Cross-Reactivity-Oriented Screening

Closely related peptides may share several amino acid residues and present similar structural features when loaded onto the same HLA allele. Counter-screening against selected peptide variants and unrelated pMHC controls can help investigate potential cross-reactivity and prioritize candidates with more selective recognition profiles.

Flexible Downstream Development

Identified TCR-mimic nanobody candidates can be evaluated for sequence characteristics, binding specificity, and recombinant expression suitability. Depending on project objectives, selected VHH sequences may proceed to affinity maturation, humanization, or further engineering for TCRm-CAR and bispecific molecule research.

Peptide-MHC Target Nanobody Discovery: Antigen Design and Preparation

The quality and composition of the target pMHC complex directly influence screening reliability. Unlike conventional protein-target nanobody discovery, TCR-mimic screening must account for the specific peptide sequence presented by a defined MHC allele. Both components should therefore be clearly established before the screening campaign begins.

1. Target Peptide Identification

The target peptide sequence is the starting point for pMHC antigen design. It may originate from a tumor-associated protein, an intracellular oncogenic protein, a tumor-specific mutation, or a viral protein. The selected peptide should be evaluated for compatibility with the intended HLA allele and the relevant biological research objective.

2. HLA Allele Selection

The HLA allele determines how a peptide is presented and contributes to the overall structure of the pMHC recognition surface. Different HLA alleles can present different peptide repertoires, even when peptides originate from the same source protein. Clearly defining the HLA restriction element is therefore essential for designing the target antigen and corresponding screening controls.

3. pMHC Complex Preparation

The target peptide must be appropriately presented by the selected MHC molecule. Depending on the project, recombinant pMHC monomers, multimers, or other compatible antigen formats may be considered. Complex assembly, peptide loading, purity, and stability should be assessed to support consistent screening conditions.

4. Negative-Control Antigen Design

Specificity evaluation requires suitable control antigens. These may include unrelated peptides presented by the same HLA allele, closely related peptide variants, or selected pMHC complexes with different HLA restriction elements. The control panel should be designed around the target peptide and the anticipated cross-reactivity risks.

Antigen Component	Information Required	Screening Purpose
Target Peptide	Peptide sequence, source protein, and relevant mutation information.	Defines the intended peptide recognition target.
HLA Allele	Specific HLA restriction element, such as HLA-A*02:01.	Defines the MHC context in which the peptide is presented.
Target pMHC Complex	Peptide-loaded MHC complex with confirmed identity and suitable quality.	Used for positive selection and target-specific binding evaluation.
Unrelated Peptide Controls	Other peptides presented by the same HLA allele.	Helps distinguish peptide-specific recognition from MHC-framework binding.
Related Peptide Variants	Sequence variants, including selected amino acid substitutions where relevant.	Evaluates potential cross-reactivity with structurally similar peptides.
HLA Control Complexes	Other HLA alleles or relevant MHC control formats.	Helps investigate HLA restriction and unwanted MHC-associated binding.

High-Specificity Screening Strategy for Peptide-MHC Target Nanobody Discovery

TCR-mimic nanobody screening must distinguish the desired peptide-MHC complex from other structurally related pMHC targets. A carefully designed positive and negative selection strategy is therefore central to candidate enrichment and specificity assessment.

Step 1. Target pMHC Assessment

Define the target peptide, HLA allele, and intended pMHC antigen format. Evaluate antigen identity, quality, and suitability for display-based screening before initiating the selection process.

Step 2. Target-Specific Positive Selection

Screen the yeast display library against the target pMHC complex to enrich VHH candidates capable of recognizing the intended peptide-HLA combination. Selection conditions should be established according to antigen presentation and screening objectives.

Step 3. Negative Selection Against Unrelated pMHC Complexes

Introduce appropriate negative-selection steps using unrelated peptide-HLA complexes and other relevant controls. This helps reduce candidates that recognize shared MHC structures or unrelated peptide-MHC combinations rather than the intended target.

Step 4. FACS-Based Candidate Enrichment

Fluorescence-activated cell sorting can be used to enrich target-binding yeast populations and compare binding signals under defined conditions. Multiple selection rounds may be considered to improve candidate enrichment and screening specificity.

Step 5. Sequence Identification and Candidate Prioritization

Enriched clones can be recovered and sequenced to identify unique VHH candidates. Sequence analysis and comparative screening results help prioritize candidates for further expression and characterization.

Step 6. Specificity and Binding Validation

Selected candidates can undergo additional binding evaluation against the target pMHC and relevant control complexes. Where suitable experimental systems are available, further assessment can investigate peptide dependence, HLA restriction, and recognition of naturally presented target pMHC on cells.

Specificity Evaluation for TCR-Mimic Nanobody Candidates

Specificity is one of the most important quality attributes in peptide-MHC target nanobody discovery. Because different peptides may share similar structural and sequence characteristics, a candidate that binds the target pMHC should also be evaluated against selected non-target complexes before being prioritized for further development.

Evaluation Parameter	Assessment Approach	What It Helps Determine
Target pMHC Binding	Binding assessment against the intended peptide-HLA complex.	Whether the candidate recognizes the intended target.
Peptide Specificity	Comparison with unrelated peptides presented by the same HLA allele.	Whether binding depends on the intended peptide rather than the shared MHC framework.
Sequence Variant Discrimination	Testing selected peptide variants, including relevant single-residue substitutions.	Whether similar peptide sequences produce unwanted cross-reactivity.
HLA Restriction	Comparison with selected alternative HLA complexes.	Whether the candidate recognizes the intended peptide-HLA context.
Binding Affinity	Quantitative binding measurements using suitable assay formats.	Binding strength and comparative candidate performance.
Cell-Surface Recognition	Evaluation using suitable HLA-matched antigen-presenting cell models.	Whether the candidate can recognize the target in a relevant cellular context.

Distinguishing Peptide Recognition from MHC Recognition

A TCR-mimic nanobody should ideally recognize the combined molecular surface formed by the target peptide and its presenting MHC molecule. If a candidate primarily interacts with conserved MHC regions, it may bind multiple unrelated peptide-MHC complexes. Comparing the target complex with appropriate control pMHC antigens helps investigate this distinction.

Assessing Cross-Reactivity with Related Peptides

Closely related peptides may differ by only one or a few amino acid residues. Depending on the target sequence and intended application, selected sequence variants can be included in the specificity panel to examine how individual peptide changes influence nanobody recognition.

Confirming Recognition in a Cellular Context

Binding to purified pMHC complexes does not automatically establish recognition of naturally processed and presented peptides on cells. When appropriate HLA-matched cell models are available, cell-based evaluation can provide additional evidence of target recognition under more biologically relevant conditions.

Important: The number and identity of negative-control pMHC complexes should be determined according to the target peptide, HLA allele, and intended application. Single-amino-acid discrimination should not be assumed for every candidate without corresponding experimental evidence.

Applications of Peptide-MHC Target Nanobody Discovery

TCR-mimic nanobodies provide an alternative recognition format for targeting intracellular-derived antigens presented on cell surfaces through MHC molecules. By recognizing selected peptide-MHC complexes, these binders can support research programs targeting antigens that are not directly accessible to conventional antibodies.

1. Tumor Neoantigen Targeting

Tumor-specific mutations can generate novel peptide sequences that are processed and presented by MHC molecules. TCR-mimic nanobodies directed against selected neoantigen-pMHC complexes may support the development of targeted therapeutic research approaches for mutation-associated tumor antigens.

2. Intracellular Oncoprotein-Derived Peptide Targeting

Many disease-associated proteins are located inside cells and cannot be directly accessed by conventional extracellular antibody binders. Their processed peptide fragments may, however, be presented on the cell surface by MHC molecules. TCR-mimic discovery provides a strategy for investigating binders against these peptide-MHC targets.

3. TCRm-CAR Development

Selected pMHC-specific nanobodies may be considered as antigen-recognition domains in TCR-mimic CAR research. Their compact structure and engineering flexibility provide opportunities for incorporating pMHC recognition into alternative CAR architectures. Further construct optimization and functional testing are required to evaluate their suitability.

4. Bispecific T-Cell Engager Development

TCR-mimic nanobodies may also serve as target-recognition components in bispecific molecule research. By combining pMHC recognition with another functional binding domain, these molecules can be investigated for their ability to facilitate target-dependent immune cell engagement.

5. Targeted Delivery and Diagnostic Research

Highly selective peptide-MHC binders may support the development of targeted delivery systems and molecular detection tools. Their potential use depends on target abundance, pMHC stability, specificity, and the characteristics of the intended molecular format.

Information Required for a Peptide-MHC Target Nanobody Discovery Project

Providing complete target information helps establish a suitable pMHC antigen preparation and screening strategy. Before initiating a project, clients are encouraged to share the following details.

Project Information	Details to Provide	Importance
Target Peptide Sequence	Full amino acid sequence of the target peptide.	Defines the peptide component of the target pMHC complex.
Source Protein	Protein name, gene name, mutation information, or UniProt ID.	Provides biological context for the target peptide.
HLA Restriction Element	Specific HLA allele, such as HLA-A*02:01 or another relevant allele.	Determines the MHC context required for peptide presentation.
pMHC Antigen Format	Available monomer, multimer, or other recombinant pMHC format.	Helps evaluate antigen compatibility and screening readiness.
Control pMHC Complexes	Unrelated peptides, sequence variants, or alternative HLA complexes, if available.	Supports specificity and cross-reactivity assessment.
Research Objectives	TCRm nanobody discovery, TCRm-CAR research, bispecific molecules, or diagnostic development.	Defines candidate selection and downstream evaluation requirements.
Validation Requirements	Binding specificity, affinity, cell recognition, or additional functional studies.	Establishes the required characterization scope.

If the pMHC antigen has not yet been prepared, clients can share the peptide sequence and HLA allele information first. The appropriate antigen preparation and screening requirements can then be discussed with the technical team.

For upstream antigen preparation, explore our Immunogen Design & Production service.

From pMHC Binder Discovery to TCR-Mimic Nanobody Development

The identification of a target-specific pMHC binder is the foundation of TCR-mimic nanobody development. Following initial screening and sequence identification, selected candidates may require additional characterization and engineering according to the intended therapeutic or research format.

Candidate Expression and Purification

Selected VHH sequences can be transferred into suitable expression constructs for recombinant production. Purified nanobodies can then undergo identity, purity, and binding-related quality assessments to support further characterization.

Affinity Maturation and Sequence Optimization

If the initial candidates require improved binding properties, additional engineering strategies may be considered. Affinity optimization should maintain the intended peptide-MHC specificity while assessing the effects of sequence changes on cross-reactivity and molecular developability.

Humanization and Molecular Engineering

Selected TCR-mimic nanobodies may undergo humanization or other molecular engineering according to the intended application. Any sequence modification should be followed by appropriate binding and specificity reassessment to confirm that the desired pMHC recognition profile is maintained.

Engineering for TCRm-CAR and Bispecific Formats

Validated pMHC-specific VHH candidates may be considered for incorporation into TCRm-CAR constructs or bispecific molecular formats. Further evaluation may investigate expression, structural compatibility, antigen-dependent recognition, and functional performance in the selected format.

Learn more about our Yeast Display VHH Discovery Service for quantitative screening and VHH candidate selection.

Typical total timeline: Approximately 19–25 weeks depending on target complexity and screening requirements.

Why Choose Us

TCRm-Oriented Screening Design

Our workflows are specifically optimized for highly selective peptide-MHC recognition.

Advanced Specificity Selection Strategies

Integrated negative screening and quantitative sorting help reduce off-target binding risks.

End-to-End Development Support

From antigen preparation and screening to engineering and characterization.

FAQs

What is a TCR-mimic nanobody, and what is its research and clinical value?

TCR-mimic (TCRm) nanobodies are engineered single-domain antibodies that specifically recognize peptide epitopes presented by major histocompatibility complex (MHC) molecules on the cell surface. By recapitulating the target recognition mode of T-cell receptors (TCRs), they combine the intracellular target accessibility of small-molecule inhibitors with the high targeting specificity of monoclonal antibodies. This unique mechanism enables precise targeting of disease-driving intracellular antigens, including cancer neoantigens and viral epitopes, unlocking new therapeutic avenues for traditionally "undruggable" targets.

What are the main application scenarios for TCR-mimic nanobodies?

TCRm nanobodies are enabling tools for next-generation targeted therapeutics and diagnostics. Core applications include:
- Oncology: Precision targeting of mutated intracellular oncoproteins (e.g., KRAS G12D/V, p53 neoantigens) inaccessible to conventional monoclonal antibodies
- Neurodegenerative Disease: Detection of disease-specific pMHC signatures associated with Alzheimer’s and Parkinson’s disease, supporting early diagnosis and disease monitoring
- Infectious Disease: Targeting of viral peptide epitopes (e.g., SARS-CoV-2, influenza) presented on infected cells, enabling rapid therapeutic development
- Basic Immunology Research: Robust reagents for visualization of antigen presentation dynamics and immune synapse formation

How do you ensure the target specificity of TCR-mimic nanobodies?

Target specificity is the primary validation criterion for our TCRm nanobody discovery workflow. All lead candidates are counter-screened against a panel of homologous pMHC complexes to achieve single-amino-acid resolution of target discrimination. Binding performance is further validated via in vitro assays（cell-based systems and protein-based systems).

What advantages does your TCR-mimic nanobody platform have over traditional TCR biologics?

Relative to conventional soluble TCRs, which are limited by poor stability and challenging manufacturing, TCRm nanobodies exhibit superior thermal stability, facile expression in bacterial or yeast systems, and flexible engineering into bispecific and cytotoxic formats. These properties reduce R&D costs and enable scalable, consistent production for research and translational development projects.

What information is required to initiate a TCR-mimic nanobody project?

Project initiation requires the target peptide sequence, corresponding MHC allele information, and any available functional or structural data for the target. Custom pMHC complex preparation services are available as needed. Pre-project feasibility consultation is recommended to optimize target selection and project design.